Hybrid coronary revascularization
Hybrid coronary revascularization (HCR) is a cardiac surgical procedure that combines traditional coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). This procedure is typically used for patients with multivessel coronary artery disease who are not suitable candidates for traditional CABG or PCI alone.
History[edit | edit source]
The concept of hybrid coronary revascularization was first introduced in the late 1990s. The procedure was developed as a less invasive alternative to traditional CABG, with the goal of reducing surgical morbidity and improving patient outcomes.
Procedure[edit | edit source]
Hybrid coronary revascularization typically involves a two-step process. The first step is a minimally invasive direct coronary artery bypass (MIDCAB) procedure, in which the surgeon bypasses the blocked coronary artery using a graft from the patient's own chest wall. The second step is a PCI procedure, in which a stent is inserted into the blocked artery to help keep it open.
Advantages[edit | edit source]
The main advantage of hybrid coronary revascularization is that it combines the benefits of both CABG and PCI. The CABG component of the procedure allows for complete revascularization of the heart, while the PCI component allows for a less invasive approach and faster recovery time.
Risks and Complications[edit | edit source]
As with any surgical procedure, hybrid coronary revascularization carries certain risks and potential complications. These may include bleeding, infection, stroke, and heart attack. However, the risk of these complications is generally lower with HCR than with traditional CABG or PCI alone.
Future Directions[edit | edit source]
While hybrid coronary revascularization is currently used in a select group of patients, ongoing research and technological advancements may expand its use in the future. Studies are currently underway to further evaluate the safety and efficacy of this procedure, and to compare it with traditional CABG and PCI.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD